To review the efficacy and safety of first- and newer-generation antihistamines for the management of allergic rhinitis and chronic idiopathic urticaria (CIU), with a focus on management in the pharmacy.
DATA SOURCES
A literature review was performed using MEDLINE (1966–October 2005), with no time or language restrictions. Key words or phrases used were histamine, antihistamine(s), first- and second-generation, allergic rhinitis, chronic idiopathic urticaria, quality of life, impairment, sedation, cost-effectiveness, astemizole, cetirizine, desloratadine, diphenhydramine, fexofenadine, loratadine, hydroxyzine, ketotifen, and mizolastine. Additional references were found in the bibliographies of the articles cited.
STUDY SELECTION AND DATA EXTRACTION
Clinical trials and other experimental studies of the use of antihistamines for the management of allergic rhinitis and CIU were selected. Review papers and guidelines were also included.
DATA SYNTHESIS
First-generation antihistamines are effective at ameliorating the symptoms of allergic rhinitis and CIU; however, they are associated with adverse effects due to a lack of selectivity for the histamine H1-receptor and an ability to bind to cerebral H1-receptors. Newer-generation agents, in general, possess high H1-receptor selectivity and a low tendency to cross the blood–brain barrier, while maintaining efficacy. In general, safety at elevated doses has been demonstrated for the newer antihistamines, although higher rates of sedation and impairment have been reported with increasing doses for some agents.
CONCLUSIONS
Pharmacists can play an important role in the management of allergic rhinitis and CIU by considering the relative advantages of newer-generation agents when reviewing treatment options.
. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet1998;351:1225–32.
2.
. WrightALHolbergCJMartinezFDHalonenMMorganWTaussigLM.Epidemiology of physician-diagnosed allergic rhinitis in childhood. Pediatrics1994;94:895–901.
3.
. BergerWE.Overview of allergic rhinitis. Ann Allergy Asthma Immunol2003;90:7–12.
. BousquetJvan CauwenbergePKhaltaevN, Aria Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol2001;108(suppl 5):S147–334.
16.
. CasaleTBBlaissMSGelfandEGilmoreTHarveyPDHindmarchI, Antihistamine Impairment Roundtable. First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol2003;111:S835–42.
17.
. ZarebaWMossAJRoseroSZHajj-AliRKoneckiJAndrewsM.Electrocardiographic findings in patients with diphenhydramine overdose. Am J Cardiol1997;80:1168–73.
18.
. JumbelicMIHanzlickRCohleS.Alkylamine antihistamine toxicity and review of pediatric registry of the National Association of Medical Examiners. Am J Forensic Med Pathol1997;18:65–9.
19.
. GoetzCMLopezGDeanBSKrenzelokEP.Accidental childhood death from diphenhydramine overdosage. Am J Emerg Med1990;8:321–2.
20.
. Le BlayeIDonatiniBHallMKruppP.Acute ketotifen overdosage. A review of present clinical experience. Drug Saf1992;7:387–92.
21.
. QidwaiJCWatsonGSWeilerJM.Sedation, cognition, and antihistamines. Curr Allergy Asthma Rep2002;2:216–22.
22.
. CraftTM.Torsade de pointes after astemizole overdose. Br Med J (Clin Res Ed)1986;292:660.
23.
. MonahanBPFergusonCLKilleavyESLloydBKTroyJCantilenaLRJr.Torsades de pointes occurring in association with terfenadine use. JAMA1990;264:2788–90.
24.
. HindmarchIShamsiZ.Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side-effects. Clin Exp Allergy1999;29(suppl 3):133–42.
25.
. ShamsiZHindmarchI.Sedation and antihistamines: a review of inter-drug differences using proportional impairment ratios. Hum Psychopharmacol2000;15(S1):S3–30.
26.
. YanaiKRyuJHWatanabeTIwataRIdoTSawaiYHistamine H1 receptor occupancy in human brains after single oral doses of histamine H1 antagonists measured by positron emission tomography. Br J Pharmacol1995;116:1649–55.
27.
. TashiroMMochizukiHIwabuchiKSakuradoYItohMWatanabeTRoles of histamine in regulation of arousal and cognition: functional neuroimaging of histamine H1 receptors in human brain. Life Sci2002;72:409–14.
28.
. PrattCBrownAMRampeDMasonJRussellTReynoldsRCardiovascular safety of fexofenadine HCl. Clin Exp Allergy1999;29(suppl 3):212–6.
29.
. DockhornRBergnerAConnellJTFalliersCJGrabiecSVWeilerJMSafety and efficacy of loratadine (SCH-29851): a new non-sedating antihistamine in seasonal allergic rhinitis. Ann Allergy1987;58:407–11.
30.
. IranderKOdkvistLMOhlanderB.Treatment of hay fever with loratadine—a new non-sedating antihistamine. Allergy1990;45:86–91.
31.
. FalliersCBrandonMLBuchmanEConnellJTDockhornRLeesePTDouble-blind comparison of cetirizine and placebo in the treatment of seasonal rhinitis. Ann Allergy1991;66:257–62.
32.
. LockeyRFWidlitzMDMitchellDQLumryWDockhornRWoehlerTComparative study of cetirizine and terfenadine versus placebo in the symptomatic management of seasonal allergic rhinitis. Ann Allergy Asthma Immunol1996;76:448–54.
33.
. SimonsFEPrennerBMFinnAJr, Desloratadine Study Group. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol2003;111:617–22.
34.
. SalmunLMLorberR.24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139]. BMC Fam Pract2002;3:14.
35.
. BernsteinDISchoenwetterWFNathanRAStormsWAhlbrandtRMasonJ.Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol1997;79:443–8.
36.
. BronskyEAFalliersCJKaiserHBAhlbrandtRMasonJM.Effectiveness and safety of fexofenadine, a new nonsedating H1-receptor antagonist in the treatment of fall allergies. Allergy Asthma Proc1998;19:135–41.
37.
. DayJHBriscoeMPClarkRHEllisAKGervaisP.Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis. Ann Allergy Asthma Immunol1997;79:163–72.
38.
. DayJHBriscoeMWidlitzMD.Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit. J Allergy Clin Immunol1998;101:638–45.
39.
. DayJHBriscoeMRafeiroEChapmanDKramerB.Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo on an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system. Ann Allergy Asthma Immunol2001;87:474–81.
40.
. MeltzerEOWeilerJMWidlitzMD.Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. J Allergy Clin Immunol1996;97:617–26.
41.
. HermanDArnaudADryJLatilGPauliGPerrin-FayolleM[Clinical effectiveness and tolerance of loratadine versus cetirizine in the treatment of seasonal allergic rhinitis] French. Allerg Immunol (Paris)1992;244:270–4.
42.
. NunesCLadeiraS.Double-blind study of cetirizine and loratadine versus placebo in patients with allergic rhinitis. J Investig Allergol Clin Immunol2000;10:20–3.
43.
. van CauwenbergePJuniperEF.Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy2000;30:891–9.
44.
. PrennerBMCapanoDHarrisAG.Efficacy and tolerability of loratadine versus fexofenadine in the treatment of seasonal allergic rhinitis: a double-blind comparison with crossover treatment of nonresponders. Clin Ther2000;22:760–9.
45.
. WilsonAMHaggartKSimsEJLipworthBJ.Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clin Exp Allergy2002;32:1504–9.
46.
. HowarthPHSternMARoiLReynoldsRBousquetJ.Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once-daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol1999;104:927–33.
47.
. HampelFRatnerPMansfieldLMeevesSLiaoYGeorgesG.Fexofenadine hydrochloride, 180 mg, exhibits equivalent efficacy to cetirizine, 10 mg, with less drowsiness in patients with moderate-to-severe seasonal allergic rhinitis. Ann Allergy Asthma Immunol2003;91:354–61.
48.
. HorakFStubnerPZieglmayerRKavinaADe VosCBurtinBControlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis. Int Arch Allergy Immunol2001;125:73–9.
49.
. DayJHBriscoeMPRafeiroEHewlettDJrChapmanDKramerB.Randomized double-blind comparison of cetirizine and fexofenadine after pollen challenge in the environmental exposure unit: duration of effect in subjects with seasonal allergic rhinitis. Allergy Asthma Proc2004;25:59–68.
50.
. GraftDFBernsteinDIGoldsobelAMeltzerEOPortnoyJLongJ.Safety of fexofenadine in children treated for seasonal allergic rhinitis. Ann Allergy Asthma Immunol2001;87:22–6.
51.
. WahnUMeltzerEOFinnAFJrKowalskiMLDecostaPHedlinGFexofenadine is efficacious and safe in children (aged 6–11 years) with seasonal allergic rhinitis. J Allergy Clin Immunol2003;111:763–9.
52.
. LutskyBNKlosePMelonJMenardoJLMolkhouPRonchettiRA comparative study of the efficacy and safety of loratadine syrup and terfenadine suspension in the treatment of 3- to 6-year-old children with seasonal allergic rhinitis. Clin Ther1993;15:855–65.
53.
. AllegraLPaupeJWiesemanHGBaeldeY.Cetirizine for seasonal allergic rhinitis in children aged 2–6 years. A double-blind comparison with placebo. Pediatr Allergy Immunol1993;4:157–61.
54.
. PearlmanDSLumryWRWinderJANoonanMJ.Once-daily cetirizine effective in the treatment of seasonal allergic rhinitis in children aged 6 to 11 years: a randomized, double-blind, placebo-controlled study. Clin Pediatr1997;36:209–15.
55.
. SimonsFER.Prospective, long-term safety evaluation of the H1-receptor antagonist cetirizine in very young children with atopic dermatitis. ETAC Study Group. Early Treatment of the Atopic Child. J Allergy Clin Immunol1999;104:433–40.
56.
. RossiGAToscaMAPassalacquaGBianchiBLe GrazieCCanonicaGW.Evidence of desloratadine syrup efficacy and tolerability in children with pollen-induced allergic rhinitis. Allergy2005;60:416–7.
57.
. BloomMStaudingerHHerronJ.Safety of desloratadine syrup in children. Curr Med Res Opin2004;20:1959–65.
58.
. Sienra-MongeJJGazca-AguilarADel Rio-NavarroB.Double-blind comparison of cetirizine and loratadine in children ages 2 to 6 years with perennial allergic rhinitis. Am J Ther1999;6:149–55.
59.
. BlackAKGreavesMW.Antihistamines in urticaria and angioedema. Clin Allergy Immunol2002;17:249–86.
60.
. MonroeEW.Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis. Clin Ther1992;14:17–21.
61.
. LeynadierFDuarte-RisselinCMurrietaM.Comparative therapeutic effect and safety of mizolastine and loratadine in chronic idiopathic urticaria. URTILOR study group. Eur J Dermatol2000;10:205–11.
62.
. BrenemanDBronskyEABruceSKalivasJTKleinGLRothHLCetirizine and astemizole therapy for chronic idiopathic urticaria: a double-blind, placebo-controlled, comparative trial. J Am Acad Dermatol1995;33:192–8.
63.
. La RosaMLeonardiSMarcheseGCorriasABarberioGOggianoNDouble-blind multicenter study on the efficacy and tolerability of cetirizine compared with oxatomide in chronic idiopathic urticaria in preschool children. Ann Allergy Asthma Immunol2001;87:48–53.
64.
. RingJHeinRGaugerABronskyEMillerB.Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol2001;40:72–6.
65.
. MonroeEFinnAPatelPGuerreroRRatnerPBernsteinD, Desloratadine Urticaria Study Group. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol2003;48:535–41.
66.
. PaulEBerth-JonesJOrtonneJ-PSternM.Fexofenadine hydrochloride in the treatment of chronic idiopathic urticaria: a placebo-controlled, parallel-group, dose-ranging study. J Dermatolog Treat1998;9:143–9.
67.
. FinnAFJrKaplanAPFretwellRQuRLongJ.A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol1999;104:1071–8.
68.
. HandaSDograSKumarB.Comparative efficacy of cetirizine and fexofenadine in the treatment of chronic idiopathic urticaria. J Dermatolog Treat2004;15:55–7.
. NolenTM.Sedative effects of antihistamines: safety, performance, learning, and quality of life. Clin Ther1997;19:39–55.
73.
. MattilaMJPaakkariI.Variations among non-sedating antihistamines: are there real differences?Eur J Clin Pharmacol1999;55:85–93.
74.
. HarveyRPWegsJSchocketAL.A controlled trial of therapy in chronic urticaria. J Allergy Clin Immunol1981;68:262–6.
75.
. MonroeEWCohenSHKalbfleischJSchulzCI.Combined H1 and H2 antihistamine therapy in chronic urticaria. Arch Dermatol1981;117:404–7.
76.
. MaloneDCLawsonKASmithDHArrighiHMBattistaC.A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol1997;99:22–7.
77.
. SullivanPWFollinSLNicholMB.Transitioning the second-generation antihistamines to over-the-counter status: a cost-effectiveness analysis. Med Care2003;41:1382–95.
78.
. FiremanP.Treatment of allergic rhinitis: effect on occupation productivity and work force costs. Allergy Asthma Proc1997;18:63–7.
79.
. BlaissMS.Cost-effectiveness of H1-antihistamines. Clin Allergy Immunol2002;17:319–36.
